Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations

Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations

BACKGROUND: Moxifloxacin (MFX) and linezolid (LZD) are key components of rifampicin-resistant TB treatment regimens. Currently, available dispersible tablet formulations of both drugs have poor palatability in children. We evaluated children’s preferences for more child-friendly formulations from tw...

Full description

Saved in:
Bibliographic Details
Main Authors: G. Hoddinott, H.R. Draper, N. Vanqa, S. Myeni, S. Staples, T. Sachs, M. Raffique, N. Tshethu, M. Palmer, L. Viljoen, K. Inabathina, R. Taneja, A.C. Hesseling, A.J. Garcia-Prats
Format: Article
Language:English
Published: International Union Against Tuberculosis and Lung Disease (The Union) 2025-04-01
Series:IJTLD Open
Subjects:
rifampicin-resistant
moxifloxacin
linezolid
acceptability
palatability
children
Online Access:https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000004/art00004
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items